With a targeted disruptive innovation biotechnology-related exchange traded fund strategy, investors can focus on companies driving change in targeted therapeutics, bioinformatics, CRISPR technology, and more.
Thanks to DNA sequencing and the genomic revolution, we could be on the cusp of a brand-new era of healthcare solutions that could extend and enhance the quality of human life.
While disruptive innovation strategies may experience short-term volatility, ARK’s research shows that maintaining a long-term time horizon is critical.